Suppr超能文献

在一名高度致敏的儿科患者中,通过ABO血型不相容和配对交换肾移植优化人类白细胞抗原匹配。

Optimizing HLA matching in a highly sensitized pediatric patient using ABO-incompatible and paired exchange kidney transplantation.

作者信息

Nayak Anjali B, Ettenger Robert B, McGuire Suzanne, Lipshutz Gerald S, Reed Elaine F, Veale Jeffrey, Tsai Eileen W

机构信息

Department of Pediatrics, OU Childrens, University of Oklahoma Health Sciences Center, 1200 N Children's Avenue, Suite 14200, Oklahoma City, OK, 73104, USA,

出版信息

Pediatr Nephrol. 2015 May;30(5):855-8. doi: 10.1007/s00467-015-3064-z. Epub 2015 Mar 8.

Abstract

BACKGROUND

Kidney transplantation is the treatment of choice for end-stage renal disease. However, since pediatric patients have long projected life-years, it is also optimal for them to get well-matched transplants to minimize long-term sensitization. In North America, pediatric kidney transplantation is largely dependent upon the use of deceased donor organs, making it challenging to identify timely, well-matched transplants. Pediatric recipients may have willing living donors who are either HLA- or ABO-incompatible (ABOi); therefore, one solution is to utilize ABOi transplants and paired exchange programs to enhance HLA matching and living donation.

CASE-DIAGNOSIS/TREATMENT: We adopted this approach for a highly sensitized patient with cPRA 90%, who received a successful ABOi paired exchange transplant. The recipient received pre-transplant immunomodulation until an acceptable isohemagglutinin titer <1:8 was reached before transplantation. The patient was induced with anti-thymocyte globulin and maintained on steroid-based triple immunosuppression. Eighteen-month allograft function is excellent with an estimated glomerular filtration rate (eGFR) of 83.53 ml/min/1.73 m(2). The patient did not develop de novo donor-specific HLA antibodies or have any episodes of acute rejection

CONCLUSIONS

This case highlights the safety and efficacy of using paired exchange in combination with ABOi transplants in pediatric kidney transplantation to optimize HLA matching, minimize wait times, and enhance allograft survival.

摘要

背景

肾移植是终末期肾病的首选治疗方法。然而,由于儿科患者预期寿命较长,接受匹配良好的移植以尽量减少长期致敏对他们来说也是最佳选择。在北美,儿科肾移植很大程度上依赖于使用已故供体器官,因此难以找到及时且匹配良好的移植供体。儿科受者可能有意愿捐献的活体供者,但这些供者要么与受者 HLA 不匹配,要么 ABO 血型不相容(ABOi);因此,一种解决方案是利用 ABOi 移植和配对交换计划来提高 HLA 匹配度并增加活体捐献。

病例诊断/治疗:我们对一名高度致敏且交叉配型反应抗体(cPRA)为 90%的患者采用了这种方法,该患者接受了一次成功的 ABOi 配对交换移植。受者在移植前接受免疫调节,直至移植前达到可接受的同种血凝素滴度<1:8。患者接受抗胸腺细胞球蛋白诱导,并维持基于类固醇的三联免疫抑制治疗。移植 18 个月时,移植肾功能良好,估计肾小球滤过率(eGFR)为 83.53 ml/min/1.73 m²。患者未产生新的供体特异性 HLA 抗体,也未发生任何急性排斥反应。

结论

本病例突出了在儿科肾移植中使用配对交换与 ABOi 移植相结合的安全性和有效性,以优化 HLA 匹配、缩短等待时间并提高移植肾存活率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验